HomeNewsBusinessMoneycontrol ResearchGland Pharma: Does it still offer value after a strong run?

Gland Pharma: Does it still offer value after a strong run?

Though the management mentions that Cenexi has a decent clientele and the order book can be leveraged, an investment of 30 million euros is needed for its revamp

Anubhav Sahu

April 10, 2024 / 10:09 IST

Gland Pharma: Does it still offer value after a strong run?

Gland Pharma continues to identify molecules from the US basket, with a potential to enter Europe and Australia

Watch Webinar

PRO Panorama

Moneycontrol Pro Panorama | Silver: A market in turmoil

Oct 13, 2025 / 03:23 PM IST

In Moneycontrol Pro Panorama October 13 edition: Escalating US-China trade war poses major risks to world, some trade tips for Ind...
Read Now
PRO Weekender

Moneycontrol Pro Weekender | India Earnings Season: Why Q2 doesn't matter, and the rusty nail of US tariffs

Oct 11, 2025 / 10:00 AM IST

The September quarter results may be largely irrelevant--sandwiched between export front-loading before Trump's tariff deadline an...
Read Now

Unlock This Article

Are you a PRO subscriber? Sign In

What Do You Get

Ad free Experience

Seamless navigation, faster responses.
Expert Perspective

Explore 230+ exclusive editorials every month
+

Uncover Insights from World-Renowned Experts and Journalists
Actionable Insights

40+ weekly investment ideas + 3 to 4 daily technical calls
Virtual Events

Exclusive Live Webinars for Expert Trading & Investment Strategies!
Newsletters

Stay ahead with daily and weekly insights

View Offers

Unlock exclusive discounts

Disclosure & Disclaimer

This Research Report / Research Recommendation has been published by Moneycontrol Dot Com India Limited (hereinafter referred to as “MCD”) which is a registered Investment Advisor under the Securities and Exchange Board of India (Investment Advisers) ...Read More